KALEIDO BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0001 USD | 0.00% |
|
0.00% | +9,900.00% |
| 2022 | Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P Global BMI Index | CI |
| 2022 | Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P TMI Index | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 |
|---|---|---|---|
| Capitalization 1 | 150.8 | 327.4 | 101.8 |
| Enterprise Value (EV) 1 | 100 | 302.2 | 85.02 |
| P/E ratio | -1.49 x | -3.73 x | -1.11 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | 335,832,979 x | 92,210,594 x |
| EV / Revenue | - | 309,973,492 x | 77,011,319 x |
| EV / EBITDA | -1.17 x | -3.92 x | -1 x |
| EV / FCF | -2,011,801 x | -8,254,446 x | -1,847,308 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 3.09 x | 16 x | 9.6 x |
| Nbr of stocks (in thousands) | 30,041 | 35,982 | 42,594 |
| Reference price 2 | 5.020 | 9.100 | 2.390 |
| Announcement Date | 3/2/20 | 3/3/21 | 4/1/22 |
1USD in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | 0.975 | 1.104 |
| EBITDA 1 | -9.337 | -26.71 | -59.89 | -85.34 | -77.05 | -85.16 |
| EBIT 1 | -9.436 | -27.03 | -60.68 | -86.66 | -78.87 | -87.52 |
| Operating Margin | - | - | - | - | -8,089.64% | -7,927.72% |
| Earnings before Tax (EBT) 1 | -9.685 | -27.56 | -61.74 | -86.33 | -81.62 | -90.29 |
| Net income 1 | -9.685 | -27.56 | -61.74 | -86.33 | -81.62 | -90.29 |
| Net margin | - | - | - | - | -8,371.28% | -8,178.26% |
| EPS 2 | -2.581 | -6.166 | -12.09 | -3.359 | -2.440 | -2.157 |
| Free Cash Flow | - | -13.59 | -26.4 | -49.72 | -36.61 | -46.02 |
| FCF margin | - | - | - | - | -3,755.23% | -4,168.84% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/25/18 | 9/25/18 | 2/19/19 | 3/2/20 | 3/3/21 | 4/1/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 2.22 | - | - | - | - | - |
| Net Cash position 1 | - | 13.5 | 61 | 50.8 | 25.2 | 16.8 |
| Leverage (Debt/EBITDA) | -0.2381 x | - | - | - | - | - |
| Free Cash Flow | - | -13.6 | -26.4 | -49.7 | -36.6 | -46 |
| ROE (net income / shareholders' equity) | - | -730% | -188% | -163% | -235% | -581% |
| ROA (Net income/ Total Assets) | - | -94.5% | -65.4% | -64.6% | -69.6% | -99.9% |
| Assets 1 | - | 29.15 | 94.48 | 133.6 | 117.3 | 90.35 |
| Book Value Per Share 2 | -3.840 | -9.270 | -16.60 | 1.620 | 0.5700 | 0.2500 |
| Cash Flow per Share 2 | 0.6200 | 6.040 | 13.10 | 2.360 | 1.280 | 0.9000 |
| Capex 1 | 0.2 | 1.41 | 3 | 3.59 | 4.02 | 1.13 |
| Capex / Sales | - | - | - | - | 412.72% | 102.26% |
| Announcement Date | 9/25/18 | 9/25/18 | 2/19/19 | 3/2/20 | 3/3/21 | 4/1/22 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +9,900.00% | 4.26K | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- KLDO Stock
- Financials Kaleido Biosciences, Inc.
